edistride
astrazeneca ab - dapagliflozin-propandiol-monohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. zusätzlich zu anderen arzneimitteln für die behandlung von typ-2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.
forxiga
astrazeneca ab - dapagliflozin-propandiol-monohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. zusätzlich zu anderen arzneimitteln für die behandlung von typ-2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.
jardiance
boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.
jardiance 25 mg filmtabletten
boehringer ingelheim (schweiz) gmbh - empagliflozinum - filmtabletten - empagliflozinum 25 mg, lactosum monohydricum 113 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.008 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 400, e 171, e 172 (flavum), pro compresso. - diabetes typ 2, prävention kardiovaskuläre ereignisse, herzinsuffizienz - synthetika
jardiance 10 mg filmtabletten
boehringer ingelheim (schweiz) gmbh - empagliflozinum - filmtabletten - empagliflozinum 10 mg, lactosum monohydricum 162.5 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.01 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 400, e 171, e 172 (flavum), pro compresso. - diabetes typ 2, prävention kardiovaskuläre ereignisse, herzinsuffizienz - synthetika
glyxambi 10 mg / 5 mg filmtabletten
boehringer ingelheim (schweiz) gmbh - empagliflozinum, linagliptinum - filmtabletten - empagliflozinum 10 mg, linagliptinum 5 mg, mannitolum, amylum pregelificatum, maydis amylum, copovidonum, crospovidonum, talcum, magnesii stearas, Überzug: hypromellosum, mannitolum, talcum, e 171, macrogolum 6000, e 172 (flavum), pro compresso obducto. - antidiabetikum - synthetika
qtern filmtabletten
astrazeneca ag - dapagliflozinum, saxagliptinum - filmtabletten - dapagliflozinum 10 mg ut dapagliflozinum propandiolum monohydricum, saxagliptinum 5 mg ut saxagliptini hydrochloridum, cellulosum microcristallinum, lactosum 40 mg, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidum hydrochloridum, natrii hydroxidum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: e 132, lacca, pro compresso obducto corresp. natrium max. 0.91 mg. - antidiabetikum - synthetika
forxiga 5 mg filmtabletten
astrazeneca ag - dapagliflozinum - filmtabletten - dapagliflozinum 5 mg zu dapagliflozinum propandiolum monohydricum 6.15 mg, cellulosum microcristallinum, lactosum 25 mg, crospovidonum, silica colloidalis hydrica, magnesium stearas, Überzug: poly(alkohol vinylicus), e 171, macrogolum 3350, talkum, e 172 (gelb), für compresso dunst. - diabetes typ-2, herzinsuffizienz, chronische nierenerkrankung - synthetika
forxiga 10 mg filmtabletten
astrazeneca ag - dapagliflozinum - filmtabletten - dapagliflozinum 10 mg zu dapagliflozinum propandiolum monohydricum 12.30 mg, cellulosum microcristallinum, lactosum 50 mg, crospovidonum, silica colloidalis anhydrica, magnesium stearas, Überzug: poly(alkohol vinylicus), e 171, macrogolum 3350, talkum, e 172 (gelb), für compresso dunst. - diabetes typ-2, herzinsuffizienz, chronische nierenerkrankung - synthetika
dapagliflozin-ratiopharm 10 mg filmtabletten
ratiopharm gmbh (3087881) - filmtablette - 10 mg